Evoke Pharma, Inc. (NASDAQ:EVOK) Short Interest Update

Evoke Pharma, Inc. (NASDAQ:EVOK) was the recipient of a significant drop in short interest in February. As of February 28th, there was short interest totalling 31,200 shares, a drop of 28.9% from the February 13th total of 43,900 shares. Based on an average daily volume of 18,400 shares, the days-to-cover ratio is presently 1.7 days. Currently, 2.2% of the shares of the stock are sold short.

Wall Street Analyst Weigh In

Separately, StockNews.com assumed coverage on shares of Evoke Pharma in a report on Wednesday, March 12th. They issued a “sell” rating for the company.

Institutional Inflows and Outflows

A hedge fund recently bought a new stake in Evoke Pharma stock. Corsair Capital Management L.P. bought a new position in shares of Evoke Pharma, Inc. (NASDAQ:EVOK) in the 3rd quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm bought 11,667 shares of the specialty pharmaceutical company’s stock, valued at approximately $56,000. Corsair Capital Management L.P. owned about 1.42% of Evoke Pharma at the end of the most recent quarter.

Evoke Pharma Trading Down 10.2 %

Shares of EVOK stock traded down $0.39 on Monday, reaching $3.43. The company’s stock had a trading volume of 48,202 shares, compared to its average volume of 119,644. The stock’s fifty day simple moving average is $4.53 and its 200-day simple moving average is $4.71. Evoke Pharma has a 1 year low of $3.33 and a 1 year high of $12.32. The company has a market capitalization of $5.10 million, a price-to-earnings ratio of -0.31 and a beta of 0.12.

Evoke Pharma (NASDAQ:EVOK) last posted its quarterly earnings data on Thursday, March 13th. The specialty pharmaceutical company reported ($0.49) EPS for the quarter, missing the consensus estimate of ($0.25) by ($0.24). The firm had revenue of $3.31 million for the quarter, compared to analysts’ expectations of $3.08 million. Evoke Pharma had a negative return on equity of 308.49% and a negative net margin of 71.32%.

About Evoke Pharma

Evoke Pharma, Inc, a specialty pharmaceutical company, primarily focuses on the development and commercialization of drugs for the treatment of gastroenterological disorders and diseases. It offers Gimoti, a metoclopramide nasal spray to treat symptoms associated with acute and recurrent diabetic gastroparesis in adults.